Lancet Rheumatology

Papers
(The H4-Index of Lancet Rheumatology is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
Global, regional, and national burden of low back pain, 1990–2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021288
Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study241
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study220
Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine218
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study215
COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study204
Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021177
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study176
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial153
Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout135
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial133
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study132
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study130
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies126
COVID-19 vasculitis and novel vasculitis mimics125
Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis122
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study118
Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment115
Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study111
COVACTA trial raises questions about tocilizumab's benefit in COVID-19104
Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases99
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study98
Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative96
Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study91
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses84
Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study83
Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?82
Viral arthritis and COVID-1974
Perspective of patients with autoimmune diseases on COVID-19 vaccination74
Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study72
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform69
Flare of rheumatoid arthritis after COVID-19 vaccination67
Too long to wait: the impact of COVID-19 on elective surgery66
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study65
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial64
First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection64
Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-1963
68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study61
B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?61
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies61
Of mice and men: converging on a common molecular understanding of osteoarthritis57
Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study57
Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Ear56
Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial56
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study55
Reactivation of IgA vasculitis after COVID-19 vaccination54
Adverse events after first COVID-19 vaccination in patients with autoimmune diseases53
Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platf51
Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 202150
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials49
0.05799412727356